BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

365 related articles for article (PubMed ID: 24115819)

  • 1. Incidence and characteristics of HBV reactivation in hematological malignant patients in south Egypt.
    Elkady A; Aboulfotuh S; Ali EM; Sayed D; Abdel-Aziz NM; Ali AM; Murakami S; Iijima S; Tanaka Y
    World J Gastroenterol; 2013 Oct; 19(37):6214-20. PubMed ID: 24115819
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy of prophylactic antiviral therapy and outcomes in HBsAg-negative, anti-HBc-positive patients receiving chemotherapy: a real-life experience.
    Papadopoulos N; Deutsch M; Manolakopoulos S; Bitsi C; Michalakeas H; Poulakidas H; Tsironi E; Giannouli S; Papatheodoridis GV; Koskinas J; Pectasides D
    Eur J Gastroenterol Hepatol; 2017 Jan; 29(1):56-60. PubMed ID: 27669175
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prevalence and chemotherapy-induced reactivation of occult hepatitis B virus among hepatitis B surface antigen negative patients with diffuse large B-cell lymphoma: significance of hepatitis B core antibodies screening.
    Elbedewy TA; Elashtokhy HE; Rabee ES; Kheder GE
    J Egypt Natl Canc Inst; 2015 Mar; 27(1):11-8. PubMed ID: 25716703
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hepatitis B virus reactivation and efficacy of prophylaxis with lamivudine in patients undergoing allogeneic stem cell transplantation.
    Giaccone L; Festuccia M; Marengo A; Resta I; Sorasio R; Pittaluga F; Fiore F; Boccadoro M; Rizzetto M; Bruno B; Marzano A
    Biol Blood Marrow Transplant; 2010 Jun; 16(6):809-17. PubMed ID: 20060484
    [TBL] [Abstract][Full Text] [Related]  

  • 5. PREVALENCE OF OCCULT HEPATITIS B INFECTION IN IRANIAN CANCER PATIENTS BEFORE CHEMOTHERAPY TREATMENT.
    Baghbanian M; Halvani M; Roghani HS; Lotfi MH; Yazdi MF; Vahedian-Ardakani HA
    Arq Gastroenterol; 2016; 53(3):175-9. PubMed ID: 27438423
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Virological and clinical characteristics on reactivation of occult hepatitis B in patients with hematological malignancy.
    Sugauchi F; Tanaka Y; Kusumoto S; Matsuura K; Sugiyama M; Kurbanov F; Ueda R; Mizokami M
    J Med Virol; 2011 Mar; 83(3):412-8. PubMed ID: 21264861
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Testing for hepatitis B infection in prospective chemotherapy patients: a retrospective study.
    Wang Y; Luo XM; Yang D; Zhang J; Zhuo HY; Zhang J; Jiang Y
    World J Gastroenterol; 2013 Feb; 19(6):923-30. PubMed ID: 23429298
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prophylactic antiviral therapy in allogeneic hematopoietic stem cell transplantation in hepatitis B virus patients.
    Liao YP; Jiang JL; Zou WY; Xu DR; Li J
    World J Gastroenterol; 2015 Apr; 21(14):4284-92. PubMed ID: 25892880
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Reactivation of hepatitis B virus in patients with undetectable HBsAg undergoing chemotherapy for malignant lymphoma or multiple myeloma.
    Matsui T; Kang JH; Nojima M; Tomonari A; Aoki H; Yamazaki H; Yane K; Tsuji K; Andoh S; Andoh S; Sakai H; Maemori M; Maguchi H; Tanaka Y
    J Med Virol; 2013 Nov; 85(11):1900-6. PubMed ID: 23926082
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prevention and management of hepatitis B virus reactivation in patients with hematological malignancies treated with anticancer therapy.
    Law MF; Ho R; Cheung CK; Tam LH; Ma K; So KC; Ip B; So J; Lai J; Ng J; Tam TH
    World J Gastroenterol; 2016 Jul; 22(28):6484-500. PubMed ID: 27605883
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hepatitis B virus reactivation in patients receiving chemotherapy for malignancies: role of precore stop-codon and basic core promoter mutations.
    Alexopoulou A; Theodorou M; Dourakis SP; Karayiannis P; Sagkana E; Papanikolopoulos K; Archimandritis AJ
    J Viral Hepat; 2006 Sep; 13(9):591-6. PubMed ID: 16907845
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Incidence of hepatitis virus infection and severe liver dysfunction in patients receiving chemotherapy for hematologic malignancies.
    Kawatani T; Suou T; Tajima F; Ishiga K; Omura H; Endo A; Ohmura H; Ikuta Y; Idobe Y; Kawasaki H
    Eur J Haematol; 2001 Jul; 67(1):45-50. PubMed ID: 11553266
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prospective study of hepatitis B virus reactivation in patients with hematological malignancies.
    Pompili M; Basso M; Hohaus S; Bosco G; Nosotti L; D'Andrea M; Fenu S; Grieco A; Laurenti L; Mirisola C; Pagano L; Rapaccini GL; Sica S; Storti S; Landolfi R
    Ann Hepatol; 2015; 14(2):168-74. PubMed ID: 25671825
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical and virological factors associated with hepatitis B virus reactivation in HBsAg-negative and anti-HBc antibodies-positive patients undergoing chemotherapy and/or autologous stem cell transplantation for cancer.
    Borentain P; Colson P; Coso D; Bories E; Charbonnier A; Stoppa AM; Auran T; Loundou A; Motte A; Ressiot E; Norguet E; Chabannon C; Bouabdallah R; Tamalet C; Gérolami R
    J Viral Hepat; 2010 Nov; 17(11):807-15. PubMed ID: 20002298
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antibody to hepatitis B core antigen as a screening test for occult hepatitis B virus infection in Egyptian chronic hepatitis C patients.
    El-Sherif A; Abou-Shady M; Abou-Zeid H; Elwassief A; Elbahrawy A; Ueda Y; Chiba T; Hosney AM
    J Gastroenterol; 2009; 44(4):359-64. PubMed ID: 19271112
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Fatal reactivation of hepatitis B virus in a patient who was hepatitis B surface antigen negative and core antibody positive before receiving chemotherapy for non-Hodgkin lymphoma.
    Wu JM; Huang YH; Lee PC; Lin HC; Lee SD
    J Clin Gastroenterol; 2009; 43(5):496-8. PubMed ID: 19247200
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Reactivation of occult hepatitis B virus infection following cytotoxic lymphoma therapy in an anti-HBc negative patient.
    Feeney SA; McCaughey C; Watt AP; Agnaf MR; McDougall N; Wend UC; Gerlich WH; Coyle PV
    J Med Virol; 2013 Apr; 85(4):597-601. PubMed ID: 23359331
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Kinetics of viral loads and risk of hepatitis B virus reactivation in hepatitis B core antibody-positive rheumatoid arthritis patients undergoing anti-tumour necrosis factor alpha therapy.
    Lan JL; Chen YM; Hsieh TY; Chen YH; Hsieh CW; Chen DY; Yang SS
    Ann Rheum Dis; 2011 Oct; 70(10):1719-25. PubMed ID: 21719446
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Association of Hepatitis B Core-Related Antigen With Hepatitis B Virus Reactivation in Occult Viral Carriers Undergoing High-Risk Immunosuppressive Therapy.
    Seto WK; Wong DK; Chan TS; Hwang YY; Fung J; Liu KS; Gill H; Lam YF; Cheung KS; Lie AK; Lai CL; Kwong YL; Yuen MF
    Am J Gastroenterol; 2016 Dec; 111(12):1788-1795. PubMed ID: 27644733
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Reactivation of hepatitis B virus infection after cytotoxic chemotherapy or immunosuppressive therapy.
    Manzano-Alonso ML; Castellano-Tortajada G
    World J Gastroenterol; 2011 Mar; 17(12):1531-7. PubMed ID: 21472116
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.